On July 4th, Beijing time, Financial Times reported that Sriram Krishnan, a former AI advisor to the U.S. President, revealed that the Trump administration would not implement a formal licensing framework for AI technologies. This stance comes despite the White House having previously invoked emergency powers to temporarily suspend the deployment of the most advanced AI models. Krishnan clarified that the administration has no intention of establishing an agency akin to the U.S. Food and Drug Administration (FDA) to oversee AI, emphasizing the government’s aversion to cumbersome bureaucratic processes and its commitment to avoiding artificial selection of industry winners and losers. However, this position appears to contrast with recent actions: just weeks prior, the U.S. government compelled Anthropic to withdraw its most advanced model, Mythos, and required OpenAI to delay the release of GPT-5.6, both moves justified on national security grounds.